Non Hodgkin S Lymphoma Articles & Analysis
20 news found
Each case is represented by duplicate nuclear cores, providing ample material for analysis. In addition, the Non-Hodgkin’s Lymphoma Tissue Microarray 4, 80 Cases, 42 Cores (Catalog NO. IMCT038) is a microarray focused on non-Hodgkin’s lymphoma tissues ...
Data from all three areas of scientific focus will be showcased during this year’s meeting. Bayer is progressing novel research around its prostate cancer treatment darolutamide. ...
ByBayer AG
The Peter MacCallum Cancer Centre (“Peter Mac”) and Cartherics Pty Ltd (“Cartherics”) announced today they have entered into a Collaborative Development Program Agreement (CDPA) to develop Cartherics’ proprietary autologous CAR-T cell therapy (CTH-001) for the treatment of cutaneous T-cell lymphoma (CTCL). “Patients with advanced stages of ...
With the combined acquisitions of CellPoint and AboundBio announced earlier this year, we positioned ourselves in the cell therapy space, combining the potentially disruptive manufacturing and delivery model of CellPoint (Lonza’s Cocoon®, a closed, automated manufacturing platform for cell therapy) with the ability to develop next-generation CAR-Ts, small molecules and ...
Galapagos NV (Euronext & NASDAQ: GLPG) today announced its strategy for accelerated growth and value creation, its financial results for the first nine months of 2022, and the outlook for the remainder of 2022. The results are further detailed in the Q3 2022 financial report available on the financial reports section of the website. Forward, Faster strategy to accelerate innovation ...
Ansell, MD, PhD, Professor of Medicine, Division of Hematology at the Mayo Clinic, with extensive expertise in B-cell malignancies, including both Hodgkin and non-Hodgkin lymphomas Todd A. Fehniger, MD, PhD, Professor of Medicine, Washington University School of Medicine, an internationally recognized leader in natural killer ...
AVM Biotechnology, LLC, a clinical stage company advancing AVM0703 in the treatment of Non-Hodgkin’s Lymphoma (NHL)/Leukemia, today announced that it has been awarded a Phase II Small Business Innovation Research (SBIR) grant. ...
Brian obtained his BSc. in Biology from the University of Illinois at Urbana-Champaign and an MBA from Northwestern University’s Kellogg School of Management. Pearl Chan, CFO, has 25-years financial leadership experience in the tech industry having built high-performing teams as CFO at PicMonkey, NetMotion Software, and elsewhere setting direction, executing key ...
Bristol Myers Squibb (NYSE: BMY) today announced the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended approval of Breyanzi (lisocabtagene maraleucel; liso-cel), a CD19-directed chimeric antigen receptor (CAR) T cell therapy for the treatment of adult patients with relapsed or refractory (R/R) diffuse large B-cell ...
(Nasdaq: ACET), a biotechnology company discovering and developing first-in-class allogeneic gamma delta CAR T cell therapies for cancer and other diseases, today announced positive interim data from its dose escalation Phase 1 study evaluating the safety and tolerability of ADI-001, Adicet’s investigational therapy targeting CD20 for the potential treatment of B-cell ...
(Nasdaq: ACET), a biotechnology company discovering and developing first-in-class allogeneic gamma delta T cell therapies for cancer and other diseases, today announced that the Company will host a webcast presentation on Monday, December 6, 2021 at 8:30 AM EST to discuss interim data from its dose escalation Phase 1 study evaluating the safety and tolerability of ADI-001, ...
Kheiron Medical Technologies today announced its new collaboration with researchers at Stanford University to design functional proof-of-concept deep learning models to solve clinical problems in novel ways, starting with Non-Hodgkin’s Lymphoma (NHL). With the collaboration, Kheiron, which has pioneered the development and ...
These two leaders in the field of cancer therapeutics will provide expert support and guidance as Araris continues preclinical and clinical development of its ADCs, created using the company’s proprietary linker technology and assembly method for use in multiple cancer types. ...
AVM Biotechnology, a clinical-stage company, announced today FDA permission to modify its ongoing clinical study, AVM0703-001, entitled “The WWRD Study: AVM0703 for Treatment of Leukemia or Lymphoma”. The initial protocol, a 3 x 3-based design, called for dose escalation of 3 mg/kg for each of the six cohorts, ranging from 6 mg/kg to 21 mg/kg, with a minimum of three ...
EO2463 is an innovative, off-the-shelf microbiome-peptide based cancer vaccine • EO2463 combines four microbiome-peptides of B lymphocytes-specific lineage markers designed to induce the full depletion of malignant B lymphocytes ENTEROME SA, a clinical stage biopharmaceutical company developing novel drugs based on its unique ability to de-code molecular interactions in the gut ...
ByEnterome
The study is an adaptive design/expansion cohort trial such that cohort enrollment of relapsed/refractory NonHodgkin’s Lymphoma patients for the pivotal trial can immediately follow the dose-escalation phase. ...
Additionally, a second approved trial with AVM0703 in Non-Hodgkin’s Lymphoma will be enrolling patients shortly. AVM Biotechnology also has an active Expanded Access (“Compassionate Use”) Program for AVM0703 (https://avmbiotech.com/compassionate-use/), and template documents and guidance for treating physicians ...
AVM Biotechnology has received FDA permission to proceed with clinical trials to evaluate its proprietary drug AVM0703 in the treatment of Acute Respiratory Distress Syndrome (ARDS) mediated by COVID-19 or Influenza patients. This is AVM’s second “safe to proceed” clinical trial authorization from the FDA within the past six months and demonstrates the broad ...
In hematology oncology, it is critically important to understand the genetics driving acute malignancies to quickly determine how best to address the disease. Today, Thermo Fisher Scientific announces a new portfolio of hematology-oncology assays for the Ion Torrent Genexus System* designed to enable a future in which turnaround times for next-generation sequencing (NGS) results can be reduced to ...
'According to the study the glutathione S-transferases act to inactivate chemicals so people without these GSTM1 and GSTT1 genes are less able to metabolize environmental chemicals,” said Lourdes Salvador, Founder and President of MCS America. ...